Bristol Myers: presents new cancer data
(CercleFinance.com) - Bristol Myers Squibb today announced the presentation of data from over 55 studies across its oncology portfolio in more than 10 tumors at the European Society for Medical Oncology (ESMO) 2023 Congress, to be held on 20-24 October in Madrid, Spain.
The data to be presented support the role of Opdivo and Opdivo-based combinations in the early and metastatic stages of several cancer types, particularly in patient groups with high unmet needs.
Further data will highlight the potential of repotrectinib in patients with TKI-naive and pre-treated NTRK-positive solid tumors, including non-small cell lung cancer (NSCLC), as well as the benefit of treatment with Opdualag, the fixed-dose dual immunotherapy.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The data to be presented support the role of Opdivo and Opdivo-based combinations in the early and metastatic stages of several cancer types, particularly in patient groups with high unmet needs.
Further data will highlight the potential of repotrectinib in patients with TKI-naive and pre-treated NTRK-positive solid tumors, including non-small cell lung cancer (NSCLC), as well as the benefit of treatment with Opdualag, the fixed-dose dual immunotherapy.
Copyright (c) 2023 CercleFinance.com. All rights reserved.